Get the Stockscreener App
0.00
100.00%
-0.7206
Cyclo Therapeutics Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.
See More
Previous Close:
$0.7206
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$25.21M
Revenue:
$1.13M
Net Income/Loss:
$-20.74M
P/E Ratio:
0.00
EPS:
-0.88
Net Cash Flow:
$-18.37M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$1.45
Cyclo Therapeutics Inc Stock (CYTH) Company Profile
Name
Cyclo Therapeutics Inc
Sector
Phone
386-418-8060
Address
6714 NW 16TH STREET, SUITE B, GAINESVILLE
Compare CYTH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYTH
Cyclo Therapeutics Inc
|
0.00 | 25.21M | 1.13M | -20.74M | -18.37M | -0.88 |
|
HLN
Haleon Plc Adr
|
11.14 | 48.63B | 14.35B | 1.85B | 0 | 0.4023 |
|
ZTS
Zoetis Inc
|
162.58 | 72.59B | 9.29B | 2.52B | 2.28B | 5.57 |
|
RDHL
Redhill Biopharma Ltd Adr
|
1.84 | 3.27M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.57 | 44.08B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.96 | 19.43B | 16.54B | -1.64B | 749.00M | -1.45 |
Cyclo Therapeutics Inc Stock (CYTH) Latest News
Niemann-Pick Disease Type C Market to Expand Significantly - openPR.com
Zevra Cashes in on First FDA-Approved NPC Treatment with PRV - Genetic Engineering and Biotechnology News
RFL stock touches 52-week low at $1.28 amid market challenges - Investing.com
RFL stock touches 52-week low at $1.28 amid market challenges By Investing.com - Investing.com India
Rafael Holdings, Inc. Provides Update to the Description of Subscription Rights Related to its Public Warrants in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trap - The Manila Times
Rafael Holdings Rights Offering: $25M Deal Terms Revealed, May 29 Deadline Approaches - Stock Titan
Rafael : to Present at LD Micro Investor Conference - marketscreener.com
SEC Form 424B3 filed by Rafael Holdings Inc. - Quantisnow
Rafael Holdings Reports First Quarter Fiscal 2025 Financial Results - ADVFN
Rafael Holdings, Inc. Announces Revised Subscription Rights in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™ - The Manila Times
Rafael Holdings Launches $25M Rights Offering: Key Dates and Terms Investors Must Know - Stock Titan
Hercules Capital: Q1 Earnings Snapshot - marketscreener.com
Rafael Holdings, Inc. Announces Proposed Terms of a $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™ - The Manila Times
Rafael Holdings Secures Future: $25M Rights Offering Powers Critical Phase 3 Drug Launch Plans - Stock Titan
Cyclo Therapeutics (NASDAQ:CYTH) and Genfit (NASDAQ:GNFT) Financial Comparison - Defense World
Rafael Holdings Strengthens its Focus on the Development of Trappsol® Cyclo™ and Announces Chief Executive Officer Bill Conkling Will Be Stepping Down from His Role - The Manila Times
Rafael Holdings Strengthens its Focus on the Development of Trappsol Cyclo and Announces Chief Executive Officer Bill Conkling Will Be Stepping Down from His Role - marketscreener.com
Rafael Holdings Announces Leadership Transition Following Merger with Cyclo Therapeutics and Full Enrollment of TransportNPC™ Phase 3 Trial for Niemann-Pick Disease Treatment - Nasdaq
Rafael Holdings Strengthens its Focus on the Development of Trappsol® Cyclo™ and Announces ... - Bluefield Daily Telegraph
Rafael Holdings Pivots to Breakthrough Rare Disease Drug Development as Leadership Changes - Stock Titan
Form 8-KCurrent report - ADVFN
Contrasting BioNTech (NASDAQ:BNTX) and Cyclo Therapeutics (NASDAQ:CYTH) - Defense World
Rafael Holdings finalizes merger with Cyclo Therapeutics By Investing.com - Investing.com South Africa
Rafael Closes Merger With Cyclo Therapeutics - MarketScreener
Rafael Holdings and Cyclo Therapeutics Merge - citybiz
Rafael Holdings Completes Merger With Cyclo Therapeutics Following Shareholder Approvals - MarketScreener
Cyclo Therapeutics Merges with Rafael Holdings - TipRanks
Rafael Holdings Completes Merger with Cyclo Therapeutics - TipRanks
Rafael Holdings finalizes merger with Cyclo Therapeutics - Investing.com
Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals - GlobeNewswire
Major Pharma Merger: Rafael Holdings Gains Phase 3 Rare Disease Asset in Strategic Deal - Stock Titan
Rafael Holdings secures shareholder nod for Cyclo Therapeutics merger By Investing.com - Investing.com Canada
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Rafael Holdings secures shareholder nod for Cyclo Therapeutics merger - Investing.com
Cyclo Therapeutics shareholders approve merger with Rafael Holdings By Investing.com - Investing.com South Africa
Cyclo Therapeutics shareholders approve merger with Rafael Holdings - Investing.com
WILLIAM SHANAHAN Obituary (2025)New York, NYNew York Times - Legacy.com
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
March Madness: Flutter Stock Is a Solid Bet on Sustained Growth - The Globe and Mail
Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer’s Disease from the U.S. Patent and Trademark Office - Business Wire
Q4 Earnings Highlights: Apogee (NASDAQ:APOG) Vs The Rest Of The Commercial Building Products Stocks - The Globe and Mail
Cyclo Therapeutics Announces Closing of Strategic Investment Through a $2.1 Million Private Placement from Rafael Holdings, Inc. (NYSE:RFL) - Business Wire
CYCLO THERAPEUTICS Earnings Preview: Recent $CYTH Insider Trading, Hedge Fund Activity, and More - Nasdaq
Rafael Holdings Inc Reports Q2 2025 Earnings: EPS at -$0.19, Str - GuruFocus.com
Rafael Holdings, Inc. SEC 10-Q Report - TradingView
Rafael Holdings Reports Q2 Fiscal 2025 Results - TipRanks
Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results - The Manila Times
Rafael Holdings, Inc. Reports Financial Results and Anticipates Closure of Merger with Cyclo Therapeutics in Q3 - Nasdaq
Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results - GlobeNewswire Inc.
Cyclo Therapeutics (CYTH) to Release Quarterly Earnings on Monday - Defense World
Cyclo Therapeutics secures $2.5 million in funding By Investing.com - Investing.com Australia
Cyclo Therapeutics Inc Stock (CYTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.47%
0.98%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):